457 related articles for article (PubMed ID: 11379382)
1. The rationale for a wider range of progestogens.
Skouby SO
Climacteric; 2000 Dec; 3 Suppl 2():14-20. PubMed ID: 11379382
[TBL] [Abstract][Full Text] [Related]
2. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
3. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits.
Sitruk-Ware R
Menopause; 2002; 9(1):6-15. PubMed ID: 11791081
[TBL] [Abstract][Full Text] [Related]
4. Sex steroids and breast cancer prevention.
Spicer DV; Pike MC
J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
6. Rationale for hormone replacement therapy in atherosclerosis prevention.
Wagner JD
J Reprod Med; 2000 Mar; 45(3 Suppl):245-58. PubMed ID: 10756506
[TBL] [Abstract][Full Text] [Related]
7. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
8. Balancing safety and efficacy focus on endometrial protection.
Boroditsky RS
J Reprod Med; 2000 Mar; 45(3 Suppl):273-84. PubMed ID: 10756508
[TBL] [Abstract][Full Text] [Related]
9. Micronized progesterone and its impact on the endometrium and breast vs. progestogens.
Gompel A
Climacteric; 2012 Apr; 15 Suppl 1():18-25. PubMed ID: 22432812
[TBL] [Abstract][Full Text] [Related]
10. Update on hormone replacement therapy.
Gambrell RD
Am Fam Physician; 1992 Nov; 46(5 Suppl):87S-96S. PubMed ID: 1442475
[TBL] [Abstract][Full Text] [Related]
11. [Hormone replacement therapy and cardiovascular risk].
Maffei S; De Caterina R
G Ital Cardiol; 1996 Aug; 26(8):899-940. PubMed ID: 9005173
[TBL] [Abstract][Full Text] [Related]
12. Use of HRT and the subsequent risk of cancer.
Beral V; Banks E; Reeves G; Appleby P
J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
[TBL] [Abstract][Full Text] [Related]
13. [Hormonal contraception and substitution therapy: the importance of progestogen for cardiovascular diseases].
Kuhl H
Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):653-62. PubMed ID: 1452000
[TBL] [Abstract][Full Text] [Related]
14. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
Simoncini T; Genazzani AR
Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
Mueck AO; Seeger H; Wallwiener D
Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
[TBL] [Abstract][Full Text] [Related]
16. The role of antiandrogens in hormone replacement therapy.
Schneider HP
Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
[TBL] [Abstract][Full Text] [Related]
17. Links between hormone replacement therapy and neoplasia.
Hulka BS
Fertil Steril; 1994 Dec; 62(6 Suppl 2):168S-175S. PubMed ID: 7958013
[TBL] [Abstract][Full Text] [Related]
18. [Cancer risk under hormone therapy].
Lauritzen C
Ther Umsch; 1994 Nov; 51(11):755-66. PubMed ID: 7839334
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-replacement therapy in younger women with breast cancer.
Theriault RL; Sellin RV
J Natl Cancer Inst Monogr; 1994; (16):149-52. PubMed ID: 7999457
[TBL] [Abstract][Full Text] [Related]
20. Progestogen therapies: differences in clinical effects?
Wiegratz I; Kuhl H
Trends Endocrinol Metab; 2004 Aug; 15(6):277-85. PubMed ID: 15358281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
